# Ivermectin Repurposed for the Treatment of PKDL

> **NCT07286604** · EARLY_PHASE1 · COMPLETED · sponsor: **International Centre for Diarrhoeal Disease Research, Bangladesh** · enrollment: 10 (actual)

## Conditions studied

- Post Kala Azar Dermal Leishmaniasis

## Interventions

- **DRUG:** Ivermectin 6 MG Oral Tablet (2 tablets)

## Key facts

- **NCT ID:** NCT07286604
- **Lead sponsor:** International Centre for Diarrhoeal Disease Research, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-02
- **Primary completion:** 2022-06-25
- **Final completion:** 2023-06-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286604, "Ivermectin Repurposed for the Treatment of PKDL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07286604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*